Cognition Therapeutics (CGTX) Short-Term Debt repayments (2022 - 2026)
Cognition Therapeutics (CGTX) reported Short-Term Debt repayments of $113000.0 for Q1 2026, down 4.24% year-over-year from $118000.0 in Q1 2025, and up 52.7% on a QoQ basis from $74000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 5 years of Short-Term Debt repayments data on file, last reported at $113000.0 in Q1 2026.
- Quarterly Short-Term Debt repayments fell 4.24% year-over-year to $113000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348000.0 (down 48.75% YoY) and the FY2025 annual result came in at $353000.0, down 52.23% from the prior year.
- Short-Term Debt repayments rose to $113000.0 in Q1 2026 per CGTX's latest filing, from $74000.0 in the prior quarter.
- Across five years, Short-Term Debt repayments topped out at $401000.0 in Q3 2022 and bottomed at $41000.0 in Q3 2025.
- The 5-year median for Short-Term Debt repayments is $185000.0 (2024), against an average of $200705.9.
- The widest annual swing landed in 2024, when Short-Term Debt repayments increased 8.94%; it then plunged 77.84% in 2025.
- Tracing CGTX's Short-Term Debt repayments over 5 years: stood at $205000.0 in 2022, then decreased by 12.68% to $179000.0 in 2023, then increased by 8.94% to $195000.0 in 2024, then slumped by 62.05% to $74000.0 in 2025, then soared by 52.7% to $113000.0 in 2026.
- Per Business Quant, the three latest CGTX Short-Term Debt repayments figures stand at $113000.0 (Q1 2026), $74000.0 (Q4 2025), and $41000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 113,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | 195,000.00 |
| Dec 31, 2024 | 195,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Sep 30, 2023 | 215,000.00 |
| Sep 30, 2023 | 215,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 207,000.00 |
| Mar 31, 2023 | 207,000.00 |
| Dec 31, 2022 | 205,000.00 |
| Dec 31, 2022 | 205,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Jun 30, 2022 | 396,000.00 |
| Jun 30, 2022 | 396,000.00 |
| Mar 31, 2022 | 394,000.00 |
| Mar 31, 2022 | 394,000.00 |